StockUK listing UK0GZKLSECapital Destroyer

Ion Beam Applications S.A.(0GZK) Stock Analysis

EUR --+0.00%
Reward33Low
Risk52Moderate
75%Data
Thin 4% profit margin
EUR —+0.00 (+0.00%) Previous close · LSE
Market cap 495.90M
Reward Ratingⓘ33 Low reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ52 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0GZK to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Ion Beam Applications S.A.?

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India.

AI Brief Pro

The brief on Ion Beam Applications S.A.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Ion Beam Applications S.A.?

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company is listed on the LSE in UK, with a market capitalisation of 495.90M, and a P/E ratio of 1.3x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Low (33)
Company Information
SectorN/A
IndustryN/A
Market Cap495.90M
P/E Ratio1.3163
Beta1.216
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.